RxDoctor Payments Data

Julio Rodriguez, MD

Internal Medicine · Houston, TXNPI 1316352735

Payments from drug & device makers

$82,640in general payments, 2019–2025

Across 78 payments — averaging $1059.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$82K
  • Johnson & Johnson$163
  • AstraZeneca$102
  • Novo Nordisk$78
  • Exact Sciences$73
  • Dexcom, Inc.$58
  • plus $208 from 7 others

What the payments were for

  • Food & beverage$682100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$82,640 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$97,753
Medicare patients
167
Services billed
1,132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$137,697
FarxigaDapagliflozin Propanediol92$122,448
TrulicityDulaglutide51$99,956
EliquisApixaban66$94,658
JanuviaSitagliptin Phosphate58$70,079
JardianceEmpagliflozin31$44,560
MounjaroTirzepatide21$33,279
XareltoRivaroxaban23$25,415
EntrestoSacubitril/Valsartan12$21,481
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$11,088
Breo ElliptaFluticasone/Vilanterol13$6,900
Tresiba Flextouch U-100Insulin Degludec13$5,681
Atorvastatin Calcium448$3,507
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$3,010
Gabapentin140$2,376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$78$137,69780 claims
AstraZenecaFarxiga, Breztri Aerosphere$102$133,536109 claims
Lilly USA, LLCTrulicity, Mounjaro$49$133,23572 claims
Johnson & JohnsonXarelto$163$25,41523 claims
NovartisEntresto$57$21,48112 claims
Sanofi-aventis U.S. LLCLantus$23$2,11616 claims
AbbVieSynthroid$81,958$1,41013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →